Scarica l'app Stockscreener
7.50
3.10%
-0.24
Dopo l'orario di chiusura:
7.51
0.010
+0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.74
Aprire:
$7.79
Volume 24 ore:
1.04M
Relative Volume:
0.63
Capitalizzazione di mercato:
$697.83M
Reddito:
$823.60M
Utile/perdita netta:
$-116.00M
Rapporto P/E:
-5.7692
EPS:
-1.3
Flusso di cassa netto:
$-107.30M
1 W Prestazione:
-6.95%
1M Prestazione:
+8.70%
6M Prestazione:
-5.66%
1 anno Prestazione:
-67.49%
Intervallo 1D:
$7.34
$7.79
Intervallo di 1 settimana:
$7.34
$8.245
Portata 52W:
$3.76
$25.25
Myriad Genetics Inc Stock (MYGN) Company Profile
Nome
Myriad Genetics Inc
Settore
Industria
Telefono
801-584-3600
Indirizzo
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Confronta MYGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
7.50 | 720.17M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
524.80 | 201.90B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
202.46 | 146.42B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
616.15 | 50.30B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
136.62 | 39.72B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
198.17 | 34.51B | 15.70B | 1.24B | 2.01B | 6.9036 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-21 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-12 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Iniziato | Craig Hallum | Buy |
| 2024-12-10 | Iniziato | UBS | Neutral |
| 2024-12-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Underperform |
| 2024-05-08 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Ripresa | Piper Sandler | Neutral |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Underweight |
| 2023-05-23 | Aggiornamento | Goldman | Sell → Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Iniziato | Stephens | Equal-Weight |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Sell |
| 2019-09-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Downgrade | Needham | Strong Buy → Hold |
| 2019-07-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-03-12 | Reiterato | Needham | Strong Buy |
| 2019-01-03 | Iniziato | Needham | Strong Buy |
| 2018-11-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Iniziato | Goldman | Sell |
| 2018-01-22 | Reiterato | Barclays | Equal Weight |
| 2018-01-05 | Iniziato | BTIG Research | Buy |
| 2017-10-02 | Ripresa | Leerink Partners | Mkt Perform |
| 2017-08-09 | Reiterato | Barclays | Equal Weight |
| 2017-02-08 | Aggiornamento | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Iniziato | Deutsche Bank | Sell |
| 2016-10-10 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
Mostra tutto
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage - MSN
Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know - Yahoo
Myriad Genetics: How knowing genetic risks can help women with their healthcare - KATV
Is Myriad Genetics Inc. (MYD) stock considered safe havenWeekly Profit Recap & Verified Trade Idea Suggestions - newser.com
Using RSI to spot recovery in Myriad Genetics Inc.Market Growth Review & Capital Protection Trading Alerts - newser.com
When is the best time to exit Myriad Genetics Inc.Market Weekly Review & Free High Accuracy Swing Entry Alerts - newser.com
Applying Elliott Wave Theory to Myriad Genetics Inc.Portfolio Return Report & AI Powered Trade Plan Recommendations - newser.com
News impact scoring models applied to Myriad Genetics Inc.Oil Prices & Free Risk Controlled Daily Trade Plans - newser.com
Measuring Myriad Genetics Inc.’s beta against major indicesMarket Performance Summary & Low Risk High Win Rate Stock Picks - newser.com
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV - The Manila Times
Dr. Stitt, Jodi Lavery discuss cancer screening fears, genetic testing benefits survey - KOKH
Myriad Genetics Finalizes CFO Separation Agreement - TipRanks
Myriad Genetics (NASDAQ:MYGN) Shares Pass Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Public Employees Retirement System of Ohio Raises Position in Myriad Genetics, Inc. $MYGN - MarketBeat
Why Myriad Genetics Inc. stock is popular among millennialsEarnings Summary Report & High Accuracy Trade Signal Alerts - newser.com
Will Myriad Genetics Inc. (MYD) stock gain from lower interest ratesTrade Risk Summary & Daily Stock Trend Watchlist - newser.com
Will Myriad Genetics Inc. price bounce be sustainableJuly 2025 Review & Real-Time Market Sentiment Alerts - newser.com
Will Myriad Genetics Inc. (MYD) stock deliver stable dividendsCEO Change & Long-Term Capital Growth Strategies - newser.com
Is Myriad Genetics Inc. stock attractive for passive investorsJuly 2025 Action & Verified Swing Trading Watchlist - newser.com
Heatmap analysis for Myriad Genetics Inc. and competitorsJuly 2025 Spike Watch & Low Risk High Win Rate Picks - newser.com
Is Myriad Genetics Inc. (MYD) stock ideal for retirement investorsPortfolio Performance Report & Long-Term Growth Portfolio Plans - newser.com
Should Dividend Investors Consider Tecil Chemicals and Hydro Power Ltd in 2025Automated Trading Signals & Create Passive Income With Smart Stocks - earlytimes.in
Myriad Genetics Inc Stock Analysis and ForecastDividend Stock Watch & Free Unlock Stock Analysis - earlytimes.in
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Myriad Genetics announces resignation of principal accounting officer - Investing.com
jscreen, TODAY Show & Mount Sinai Unite for Groundbreaking Cancer Genetic Screening Event in Honor of Breast Cancer Awareness Month - Yahoo Finance
United States Genomics Industryinvestments driving $115B - openPR.com
A Look Back at Therapeutics Stocks’ Q2 Earnings: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Pack - The Globe and Mail
Myriad Genetics (NASDAQ:MYGN) Shares Down 5.2%Should You Sell? - MarketBeat
Is Myriad Genetics Inc a good long term investmentPortfolio Allocation Tips & Superior Capital Trading - Early Times
Assenagon Asset Management S.A. Buys 240,643 Shares of Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad genetics lowers 2025 revenue guidance by $35M amid GeneSight challenges - MSN
Myriad Genetics and SOPHiA GENETICS partner on liquid biopsy test By Investing.com - Investing.com Canada
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy - The Manila Times
Myriad Genetics and SOPHiA GENETICS partner on liquid biopsy test - Investing.com
Myriad Genetics Inc Azioni (MYGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.17%
2.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):